Branches
Roche Singapore Pte Ltd
Key Trials
4 trials shown
Roche
A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer
This study will evaluate the efficacy of tiragolumab plus atezolizumab and carboplatin and etoposide (CE) compared with placebo plus atezolizumab and CE in participan
- Study number:
- NCT04256421
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Chemotherapy
Roche
A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer
This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with placebo plus palbociclib and fulvest
- Study number:
- NCT04191499
- Cohorts:
- 1
- Study phase:
- 2, 3
- Overall status:
- Recruiting
- Study type:
- Targeted therapy, Biomarker, Hormonal therapy
Roche
A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation
This study will evaluate the efficacy and safety of adjuvant therapy with atezolizumab plus bevacizumab compared with active surveillance in participants with completely resected o
- Study number:
- NCT04102098
- Cohorts:
- 1
- Study phase:
- 3
- Overall status:
- Active, not recruiting
- Study type:
- Immunotherapy, Targeted therapy
Roche
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene
- Study number:
- NCT04140500
- Cohorts:
- 1
- Study phase:
- 1, 2
- Overall status:
- Recruiting
- Study type:
- Immunotherapy, Targeted therapy